This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Reports of symptomatic improvement associated with the use of glucosamine and chondroitin sulfate in osteoarthritis have long been present in the lay media but more recently similar observations have been published in the medical literature. In addition to symptom relief, some preliminary reports have also asserted that a chondroprotective effect may exist. A number of biologic effects related to glucosamine and chondroitin sulfate ingestion have been contemplated, however, the actual bioavailability of these compounds is unknown and a compelling mechanism of action has yet to be formulated. The work proposed herein, a thorough investigation of the pharmacokinetics of these agents both alone and in combination, is fundamental to that understanding and of considerable importance to related ongoing investigations such as GAIT.
The aim of this study is: Phase 1: to determine the presence and fluctuation of endogenous plasma levels of glucosamine and chondroitin sulfate over a 24 hour period; Phase 2: to examine the pharmacokinetics of a single dose of glucosamine hydrochloride, chondroitin sulfate, and the combination of both over a 36 hour period; Phase 3: to examine the pharmacokinetics of glucosamine hydrochloride, chondroitin sulfate, and the combination of both, taken daily over a three month period
Showing the most recent 10 out of 535 publications
